Piper Jaffray Previews Boston Scientific's Q4 10 Earnings (BSX)

Piper Jaffray is out with its report on Boston Scientific (NYSE: BSX), previewing Q4 10 earnings before they are announced this evening.

In a note to clients, Piper Jaffray writes, "Barring a major miss relative to expectations, we think Q4 results are largely academic with the focus largely on the company's 2011 outlook.We expect Boston to finish 2010 with proforma Q4 EPS of $0.17 and full year 2010 EPS of $0.65. We estimate 2011 revenue at $7,705MM, down 1% Y/Y on a reported basis."

Piper Jaffray maintains Neutral and a $7 PT on BSX.

Shares of BSX closed Monday at $6.98, down 0.14% from Friday's close.